WO2018219093A1 - Method for constructing glrx1 gene knock-out animal model based on crispr/cas9 - Google Patents
Method for constructing glrx1 gene knock-out animal model based on crispr/cas9 Download PDFInfo
- Publication number
- WO2018219093A1 WO2018219093A1 PCT/CN2018/085432 CN2018085432W WO2018219093A1 WO 2018219093 A1 WO2018219093 A1 WO 2018219093A1 CN 2018085432 W CN2018085432 W CN 2018085432W WO 2018219093 A1 WO2018219093 A1 WO 2018219093A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sgrna
- cas9
- glrx1
- mice
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
- C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Definitions
- the invention belongs to the field of making a gene knockout animal model by using a genetic modification technology, and particularly relates to a method for constructing a Glrx1 gene knockout animal model based on CRISPR/Cas9 technology.
- the CRISPR/Cas (Clustered Regularly Interspaced Shot Palindromic repeats/CRISPR-associated) system is a technique for RNA-mediated Cas protein targeted modification of a gene of interest derived from bacterial acquired immunity.
- the Type II CRISPR/Cas9 system which has been modified by researchers, has been successfully knocked out of mammalian cells since 2013 and has now been used for gene knockout of multiple model organisms.
- the CRISPR/Cas9 system vector is simple, fast, easy to operate, time-saving and labor-saving, and is suitable for almost all species.
- CRISPR/Cas9 and TALEN Transcription Activator-like Effector Nucleases
- TALEN Transcription Activator-like Effector Nucleases
- CRISPR/Cas9 only needs to construct a single sgRNA (single guide RNA), and the efficiency is very high, the sequence selection restriction is small, only GG is needed in the genome.
- ZFNs zinc-finger nucleases
- TALEN Transcription Activator-like Effector Nucleases
- CRISPR/Cas9 Compared to TALEN, CRISPR/Cas9 caused a higher off-target effect, but the use of paired sgRNA/Cas9-D10A> truncated sgRNA or FoKI-dCas9 can greatly reduce the off-target effect.
- CRISPR/Cas9 is mainly used for targeted site knockout of gene site-directed mutagenesis (insertion or deletion), gene-spotted knock-in, simultaneous two-point mutation, deletion of small fragments, coding genes and non-coding genes (lncRNA, microRNA). .
- Glutaredoxin (Glrx) is ubiquitous in bacteria, viruses and mammals. Its expression is regulated by interferon (IFN), its molecular weight is 12kDa, it is composed of 106-107 amino acid residues, and it is thioredox.
- IFN interferon
- Trx thioredoxin
- Glrx1 is a pleiotropic cytokine with a variety of biological functions, which is closely related to the regulation of redox reaction, cell growth and inhibition of apoptosis, and certain diseases of humans, such as acquired immunodeficiency syndrome and The occurrence and development of bacterial infections are also relevant.
- Glutathione is an enzyme protein that specifically and efficiently reduces glutathionylated proteins in the body. Glrx's ability to restore glutathionylated protein activity caused by oxidative stress damage may make it a hot spot. drug. Construction of the Glrx1 knockout mouse model is of great significance for the study of oxidative stress, nutritional health and so on. However, the traditional gene knockout method has a very low success rate and has not been applied. In recent years, CRISPR/Cas9 technology has been widely used, providing possibilities for the construction of Glrx1 knockout model mice and their application in nutrition and health research.
- the object of the present invention is to provide a method for constructing a Glrx1 knockout animal model based on CRISPR/Cas9 technology.
- a method for constructing a Glrx1 knockout animal model based on CRISPR/Cas9 technology comprising the following steps:
- Step 1 Selection and design of gRNA targeting mouse Glrx1 gene
- Step 2 sgRNA vector construction
- BsaI was digested with pUC57-sgRNA vector. After 1 h of water bath at 37 °C, 1% agarose was electrophoresed to recover the digested product; then the sgRNA primer was annealed; finally, the annealed product and the recovered digested product were ligated and transformed into E. coli. Select the monoclonal for PCR, and the PCR result is positive and sent to the sequencing to verify that the correct sgRNA vector is obtained;
- Step 3 In vitro transcription of sgRNA and Cas9 mRNA using a transcription kit, and transcription of a good sgRNA for use; kit name: AM1354+AM1908, Ambion by Life Technologies;
- Step 4 Microinjection of fertilized eggs of Cas9sgRNA system (Cas9 mRNA and sgRNA); Cas9 expression plasmid is cas9D10A (plasmid #42335), Addgene;
- Step 5 Birth and identification of F0 generation mice
- Step 6 F0 mice were sexually matured and matured, and F1 mice were identified.
- step 6 F0 generation mice are backcrossed with C57BL/6J mice after sexual maturation, and F1 generation mice are tail-tailed at 1 week of age to obtain positive F1 heterozygotes.
- a Glrx1 gene knockout kit based on CRISPR-Cas9 gene knockout technology comprising:
- an sgRNA vector comprising a pUC57-sgRNA vector as a starting vector, comprising an sgRNA targeting a Glrx1 gene; the sgRNA is annealed by an sgRNA primer represented by SEQ ID NO. 1 and SEQ ID NO. 2;
- the CRISPR-Cas9 gene knockout technology-based Glrx1 gene knockout kit of the present invention preferably further comprises Cas9 mRNA or a Cas9 expression plasmid for expressing Cas9 mRNA.
- the sgRNA sequence used in this experiment is highly efficient and difficult to off target.
- the second is the optimization of the Cas9sgRNA system, which makes the mouse progeny more positive and the off-target rate low.
- the Glrx1 knockout mice produced by this technique solve the bottleneck problem of high gene off-target rate and low survival rate of animals in traditional gene knockout technology, and can be widely used in the study of dietary nutrition and health, oxidative stress and related diseases. application.
- the construction method of the Glrx1 gene knockout animal model based on CRISPR/Cas9 technology is realized by the following steps:
- Step 1 Selection and design of gRNA targeting mouse Glrx1 gene
- the Glrx-1-Cas9-KO mouse strategy was designed as shown in Figure 1. According to the strategy, design the corresponding sgRNA sequence, according to the strategy, design the corresponding sgRNA in the corresponding position of the Glrx-1 intron, order the corresponding Oligo; sgRNA sequence is as follows:
- Step 2 sgRNA vector construction
- the pUC57-sgRNA vector was digested with BsaI, and after 1 h of water bath at 37 ° C, 1% agarose was electrophoresed, and the digested product was recovered. The ordered sgRNA primers are then annealed. Finally, the annealing product and the recovered enzyme-cut product were connected, transformed into E. coli, and the monoclonal antibody was selected for PCR. The PCR result was positive and sent to sequencing verification, and the correct sgRNA vector was obtained. The vector map is shown in FIG. 2 .
- Step 3 In vitro transcription of sgRNA
- Step 4 Microinjection of fertilized eggs
- mice On the first day, intraperitoneal injection of horse gonadotropin gonadotropin 5IU/only, human chorionic gonadotropin injection after 46-48 hours, 2 female mice after injection of human chorionic gonadotropin Put the male mouse in the cage. On the fourth morning, the plug was checked and the score of the plug was 0.5 days.
- the selected fertilized eggs are transferred into the prepared M2 strips and arranged in a row (about 30-50 pieces). Place the syringe on the stage of the inverted microscope so that the strip of M2 droplets is oriented perpendicular to the operator, ie on the y-axis.
- the injection tube was inserted into the cytoplasm, and the Cas9sgRNA system (sgRNA and Cas9 mRNA) was injected.
- the Cas9 expression plasmid was cas9D10A (plasmid #42335), Addgene; and the cytoplasm was loose and the needle was quickly removed.
- the embryos were transferred to a Petri dish containing M16 medium and placed in a 37 ° C, 5% carbon dioxide incubator for 0.5-1.0 hours.
- the fertilized eggs were transplanted into the E0.5 day pseudopregnant recipient.
- F0 generation mice were born about 19-21 days after transplantation.
- the number of birth defects was 39, and the number of surviving was 38.
- the F0 generation mice were identified by tail-cutting after 1 week of birth, and 7 positive F0 mice were obtained.
- the coat color was black, the sex was 5 females and 2 males, and Figure 6 was F1.
- dNTPs 0.5 10 mmol/sample Taq DNA polymerase 0.25 5 enzyme live units / microliter template 1 ⁇ 100 ng / microliter
- Step 6 Sexual maturity and F0 mice, F1 generation mouse identification
- F0 mice were sexually matured at 8 weeks of age and C57BL/6J mice were backcrossed.
- the F1 mice were tail-tailed at 1 week of age, and 6 positive F1 heterozygotes were obtained. The list is as follows:
- the F1 generation was identified from the mRNA level and enzymatic sequencing, and the mRNA level was achieved by qPCR. The conditions were the same as above. From the sequencing results, it can be seen that the length of the 61#, 62#, 64#, 73#, 74#, 75# and wild type comparison sequences is at least -7588 bp, which means that E1-E2 is deleted.
- Example 1 differs from Example 1 in that the single-stranded DNA template and primer sequence used in step three are 2074-Glrx-gtF1.
- the other steps were the same as in Example 1; the results were the same as in Example 1.
- Example 2 differs from Example 1 in that the variety of the caged male in step 4 is preferably a C57BL/6J male.
- the other steps are the same as in the first embodiment.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本发明属于利用基因修饰技术制作基因敲除动物模型的领域,具体涉及一种基于CRISPR/Cas9技术的Glrx1基因敲除动物模型的构建方法。The invention belongs to the field of making a gene knockout animal model by using a genetic modification technology, and particularly relates to a method for constructing a Glrx1 gene knockout animal model based on CRISPR/Cas9 technology.
CRISPR/Cas(Clustered Regularly Interspaced Shot Palindromic repeats/CRISPR-associated)系统,是一种来源于细菌获得性免疫的由RNA介导Cas蛋白对目的基因进行靶向修饰的技术。经过研究者改造过的Type II CRISPR/Cas9系统自2013年成功敲除哺乳动物细胞后,现在己经被应用于多种模式生物的基因敲除。CRISPR/Cas9系统载体构建简单快速、易操作、省时省力周期短,且几乎对所有物种都适用。CRISPR/Cas9和TALEN(Transcription Activator-like Effector Nucleases)的作用都是实现染色体上特定位点的双链断裂,然后引发自主损伤修复,修复会引发插入或缺失,从而造成基因序列永久的缺失,即基因敲除。针对每个基因,CRISPR/Cas9只需要构建一个sgRNA(single guide RNA),而且效率都很高,序列选择限制较小,只需要基因组上出现GG就可以。与zinc-finger nucleases(ZFNs)and TALEN相比,CRISPR/Cas9系统具有相同或者更高的基因编辑效率,更便宜。相对于TALEN,CRISPR/Cas9引起的脱靶效应较高,但是使用成对sgRNA/Cas9-D10A>截短的sgRNA或者FoKI-dCas9可以极大的降低脱靶效应。目前,CRISPR/Cas9主要应用于基因定点突变(插入或缺失)、基因定点敲入、两位点同时突变、小片段的缺失、编码基因和非编码基因(lncRNA、microRNA)的靶向基因敲除。The CRISPR/Cas (Clustered Regularly Interspaced Shot Palindromic repeats/CRISPR-associated) system is a technique for RNA-mediated Cas protein targeted modification of a gene of interest derived from bacterial acquired immunity. The Type II CRISPR/Cas9 system, which has been modified by researchers, has been successfully knocked out of mammalian cells since 2013 and has now been used for gene knockout of multiple model organisms. The CRISPR/Cas9 system vector is simple, fast, easy to operate, time-saving and labor-saving, and is suitable for almost all species. The role of CRISPR/Cas9 and TALEN (Transcription Activator-like Effector Nucleases) is to achieve double-strand breaks at specific sites on the chromosome, and then initiate autonomous damage repair, which will cause insertion or deletion, resulting in a permanent deletion of the gene sequence, ie Gene knockout. For each gene, CRISPR/Cas9 only needs to construct a single sgRNA (single guide RNA), and the efficiency is very high, the sequence selection restriction is small, only GG is needed in the genome. Compared to zinc-finger nucleases (ZFNs) and TALEN, the CRISPR/Cas9 system has the same or higher gene editing efficiency and is cheaper. Compared to TALEN, CRISPR/Cas9 caused a higher off-target effect, but the use of paired sgRNA/Cas9-D10A> truncated sgRNA or FoKI-dCas9 can greatly reduce the off-target effect. At present, CRISPR/Cas9 is mainly used for targeted site knockout of gene site-directed mutagenesis (insertion or deletion), gene-spotted knock-in, simultaneous two-point mutation, deletion of small fragments, coding genes and non-coding genes (lncRNA, microRNA). .
谷氧还蛋白(glutaredoxin,Glrx)普遍存在于细菌、病毒和哺乳动物体内,其表达受干扰素(interferon,IFN)调控,分子量为12kDa,由106-107个氨基酸残基组成,是硫氧还蛋白(thioredoxin,Trx)家族的重要分支,作为电子供体,参与组成巯基-二硫键氧化还原酶家族,依靠谷胱甘肽(GSH)将氧化状态的蛋白质二硫键还原为巯基,以维持细胞氧化还原稳态,在细胞信号转导过程中发挥重要作用。有文献报道,在氧化应激引起的损伤中,蛋白质氧化损伤先于核酸,蛋白发生羰基化和糖基化,从而失去生物活性。大量研究表明Glrx1是一种具有多种生物学功能的多效性细胞因子,与调节氧化还原反应、细胞生长和抑制凋亡有密切关系,与人类某些疾病,如获得性免疫缺陷综合征和细菌感染等的发生、发展也相关。Glutaredoxin (Glrx) is ubiquitous in bacteria, viruses and mammals. Its expression is regulated by interferon (IFN), its molecular weight is 12kDa, it is composed of 106-107 amino acid residues, and it is thioredox. An important branch of the thioredoxin (Trx) family, as an electron donor, participates in the thiol-disulfide bond oxidoreductase family, relying on glutathione (GSH) to reduce the oxidized state protein disulfide bond to a sulfhydryl group to maintain Cell redox homeostasis plays an important role in cell signal transduction. It has been reported in the literature that in oxidative stress-induced damage, protein oxidative damage precedes nucleic acids, and proteins undergo carbonylation and glycosylation, thereby losing biological activity. Numerous studies have shown that Glrx1 is a pleiotropic cytokine with a variety of biological functions, which is closely related to the regulation of redox reaction, cell growth and inhibition of apoptosis, and certain diseases of humans, such as acquired immunodeficiency syndrome and The occurrence and development of bacterial infections are also relevant.
谷氧还蛋白是机体内能特异、高效的还原谷胱甘肽化蛋白质的一种酶蛋白,Glrx特异的恢复氧化应激损伤产生的谷胱甘肽化蛋白活性的能力可能会使其成为热点药物。构建Glrx1基因敲除小鼠模型,对于研究氧化应激、营养健康等具有重要意义。但传统的基因敲除方法成功率极低,一直未得到应用。近年来,CRISPR/Cas9技术得到广泛应用,为Glrx1基因敲除模型鼠的构建及其在营养与健康研究中的应用提供了可能性。Glutathione is an enzyme protein that specifically and efficiently reduces glutathionylated proteins in the body. Glrx's ability to restore glutathionylated protein activity caused by oxidative stress damage may make it a hot spot. drug. Construction of the Glrx1 knockout mouse model is of great significance for the study of oxidative stress, nutritional health and so on. However, the traditional gene knockout method has a very low success rate and has not been applied. In recent years, CRISPR/Cas9 technology has been widely used, providing possibilities for the construction of Glrx1 knockout model mice and their application in nutrition and health research.
发明内容Summary of the invention
本发明的目的是提供一种基于CRISPR/Cas9技术的Glrx1基因敲除动物模型的构建方法。The object of the present invention is to provide a method for constructing a Glrx1 knockout animal model based on CRISPR/Cas9 technology.
本发明的目的通过以下技术方案实现。The object of the present invention is achieved by the following technical solutions.
一种基于CRISPR/Cas9技术的Glrx1基因敲除动物模型的构建方法,包含以下步骤:A method for constructing a Glrx1 knockout animal model based on CRISPR/Cas9 technology, comprising the following steps:
步骤一:靶向小鼠Glrx1基因的gRNA的选择和设计Step 1: Selection and design of gRNA targeting mouse Glrx1 gene
在Glrx1内含子相应位置设计相应的sgRNA,其引物序列如SEQ ID NO.1和SEQ ID NO.2所示;Designing corresponding sgRNAs at corresponding positions of the Glrx1 intron, the primer sequences of which are shown in SEQ ID NO. 1 and SEQ ID NO.
步骤二:sgRNA载体构建Step 2: sgRNA vector construction
首先BsaI酶切pUC57-sgRNA载体,37℃水浴1h后,1%的琼脂糖电泳,回收酶切产物;然后将sgRNA引物进行退火;最后,连接退火产物与回收的酶切产物,转化大肠杆菌,挑选单克隆进行PCR、PCR结果呈阳性送测序验证,得到正确的sgRNA载体;First, BsaI was digested with pUC57-sgRNA vector. After 1 h of water bath at 37 °C, 1% agarose was electrophoresed to recover the digested product; then the sgRNA primer was annealed; finally, the annealed product and the recovered digested product were ligated and transformed into E. coli. Select the monoclonal for PCR, and the PCR result is positive and sent to the sequencing to verify that the correct sgRNA vector is obtained;
步骤三:采用转录试剂盒,体外转录sgRNA和Cas9mRNA,转录好的sgRNA备用;试剂盒名称:AM1354+AM1908,Ambion by Life Technologies;Step 3: In vitro transcription of sgRNA and Cas9 mRNA using a transcription kit, and transcription of a good sgRNA for use; kit name: AM1354+AM1908, Ambion by Life Technologies;
步骤四:Cas9sgRNA体系(Cas9mRNA和sgRNA)的受精卵显微注射;Cas9表达质粒为cas9D10A(plasmid#42335),Addgene;Step 4: Microinjection of fertilized eggs of Cas9sgRNA system (Cas9 mRNA and sgRNA); Cas9 expression plasmid is cas9D10A (plasmid #42335), Addgene;
步骤五:F0代小鼠出生与鉴定;Step 5: Birth and identification of F0 generation mice;
步骤六:F0小鼠性成熟配繁,F1代小鼠鉴定。Step 6: F0 mice were sexually matured and matured, and F1 mice were identified.
其中个,步骤六优选:F0代小鼠在性成熟后和C57BL/6J小鼠回交进行配繁,出生F1代小鼠在1周龄进行剪尾鉴定,得到阳性的F1代杂合子。Among them, step 6 is preferred: F0 generation mice are backcrossed with C57BL/6J mice after sexual maturation, and F1 generation mice are tail-tailed at 1 week of age to obtain positive F1 heterozygotes.
进一步优选从mRNA水平和酶解测序来鉴定F1代。It is further preferred to identify the F1 generation from mRNA levels and enzymatic sequencing.
一种基于CRISPR-Cas9基因敲除技术的Glrx1基因敲除试剂盒,包括:A Glrx1 gene knockout kit based on CRISPR-Cas9 gene knockout technology, comprising:
1)sgRNA载体,所述的sgRNA载体以pUC57-sgRNA载体为出发载体,含针对Glrx1基因的sgRNA;该sgRNA由SEQ ID NO.1和SEQ ID NO.2所示的sgRNA引物退火得到;1) an sgRNA vector comprising a pUC57-sgRNA vector as a starting vector, comprising an sgRNA targeting a Glrx1 gene; the sgRNA is annealed by an sgRNA primer represented by SEQ ID NO. 1 and SEQ ID NO. 2;
2)以及配套的检测试剂,用于检测Glrx1基因的剪切效果和评估基因敲除效率。2) and supporting detection reagents for detecting the shearing effect of the Glrx1 gene and evaluating the efficiency of gene knockout.
本发明所述的基于CRISPR-Cas9基因敲除技术的Glrx1基因敲除试剂盒,优选还包含Cas9mRNA或用于表达Cas9mRNA的Cas9表达质粒。The CRISPR-Cas9 gene knockout technology-based Glrx1 gene knockout kit of the present invention preferably further comprises Cas9 mRNA or a Cas9 expression plasmid for expressing Cas9 mRNA.
本实验难点其一在于sgRNA序列定位,本实验采用的sgRNA序列高效,不易脱靶;其二在于对Cas9sgRNA体系的优化,使小鼠后代阳性率更高,脱靶率低。应用该技术制作的Glrx1敲除小鼠解决了传统基因敲除技术中基因脱靶率高、动物成活率低等瓶颈问题,可广泛应用在膳食营养与健康、氧化应激及相关疾病的研究中的应用。One of the difficulties in this experiment lies in the sgRNA sequence localization. The sgRNA sequence used in this experiment is highly efficient and difficult to off target. The second is the optimization of the Cas9sgRNA system, which makes the mouse progeny more positive and the off-target rate low. The Glrx1 knockout mice produced by this technique solve the bottleneck problem of high gene off-target rate and low survival rate of animals in traditional gene knockout technology, and can be widely used in the study of dietary nutrition and health, oxidative stress and related diseases. application.
图1、Glrx-1-Cas9-KO小鼠策略设计图Figure 1. Glrx-1-Cas9-KO mouse strategy design
图2、sgRNA载体图谱Figure 2. sgRNA vector map
图3、PCR检测策略Figure 3. PCR detection strategy
图4、61#,62#,64#电泳结果Figure 4, 61#, 62#, 64# electrophoresis results
图5、73#,74#,75#电泳结果Figure 5, 73 #, 74 #, 75 # electrophoresis results
图6、7周龄雄性纯合Glrx1 -/-小鼠照片 Figure 6 and 7 weeks old male homozygous Glrx1 -/- mice photos
实施例1Example 1
基于CRISPR/Cas9技术的Glrx1基因敲除动物模型的构建方法通过以下步骤实现:The construction method of the Glrx1 gene knockout animal model based on CRISPR/Cas9 technology is realized by the following steps:
步骤一:靶向小鼠Glrx1基因的gRNA的选择和设计Step 1: Selection and design of gRNA targeting mouse Glrx1 gene
设计Glrx-1-Cas9-KO小鼠策略,如图1所示。根据策略,设计相应sgRNA序列,根据策略,在Glrx-1内含子相应位置设计相应的sgRNA,订购相应Oligo;sgRNA序列如下:The Glrx-1-Cas9-KO mouse strategy was designed as shown in Figure 1. According to the strategy, design the corresponding sgRNA sequence, according to the strategy, design the corresponding sgRNA in the corresponding position of the Glrx-1 intron, order the corresponding Oligo; sgRNA sequence is as follows:
步骤二:sgRNA载体构建Step 2: sgRNA vector construction
首先BsaI酶切pUC57-sgRNA载体,37℃水浴1h后,1%的琼脂糖电泳,回收酶切产物。然后将订购的sgRNA引物进行退火。最后,连接退火产物与回收的酶切产物,转化大肠杆菌, 挑选单克隆进行PCR,PCR结果呈阳性送测序验证,得到正确的sgRNA载体,载体图谱如图2所示。First, the pUC57-sgRNA vector was digested with BsaI, and after 1 h of water bath at 37 ° C, 1% agarose was electrophoresed, and the digested product was recovered. The ordered sgRNA primers are then annealed. Finally, the annealing product and the recovered enzyme-cut product were connected, transformed into E. coli, and the monoclonal antibody was selected for PCR. The PCR result was positive and sent to sequencing verification, and the correct sgRNA vector was obtained. The vector map is shown in FIG. 2 .
步骤三:sgRNA体外转录Step 3: In vitro transcription of sgRNA
采用转录试剂盒,体外转录sgRNA和Cas9mRNA,转录好的sgRNA和Cas9mRNA备用。试剂盒名称:AM1354+AM1908,购自Ambion公司.The sgRNA and Cas9 mRNA were transcribed in vitro using a transcription kit, and the sgRNA and Cas9 mRNA were transcribed for later use. Kit name: AM1354+AM1908, purchased from Ambion.
步骤四:受精卵显微注射Step 4: Microinjection of fertilized eggs
1.准备单细胞受精卵1. Prepare single cell fertilized eggs
小鼠超排:第一天,腹腔注射马绒毛膜促性腺激素5IU/只,46-48小时后注射人绒毛膜促性腺激素,注射完人绒毛膜促性腺激素后将2只雌鼠与单放雄鼠合笼。第四天上午检栓,见栓的记为0.5天。Superovulation in mice: On the first day, intraperitoneal injection of horse gonadotropin gonadotropin 5IU/only, human chorionic gonadotropin injection after 46-48 hours, 2 female mice after injection of human chorionic gonadotropin Put the male mouse in the cage. On the fourth morning, the plug was checked and the score of the plug was 0.5 days.
获取受精卵:脱颈椎处死见栓0.5天的小鼠,剪出输卵管,用显微镊取出成团的卵子,透明质酸酶消化后,挑选形态饱满、胞质均匀的胚胎于M16中培养。Obtaining fertilized eggs: mice that had been sacrificed for 0.5 days after cervical vertebrae were removed, the fallopian tubes were cut out, and the mice were removed with microscopic sputum. After digestion with hyaluronidase, embryos with full morphology and uniform cytoplasm were selected and cultured in M16.
2.显微注射受精卵2. Microinjection of fertilized eggs
将挑选的受精卵转移入准备好的M2条带中,排成一列(30-50枚左右)。将注射皿放在倒置显微镜的载物台上,使M2液滴长条的方向与操作者垂直,即位于y轴上。将注射管刺入胞浆内,注入Cas9sgRNA体系(sgRNA和Cas9mRNA),Cas9表达质粒为cas9D10A(plasmid#42335),Addgene;见到胞质松散后迅速退针。注射结束后,将胚胎转移至含有M16培养液的培养皿中,放入37℃、5%二氧化碳培养箱恢复0.5-1.0小时。将受精卵移植到E0.5天假孕受体内。移植后大约19-21天出生F0代小鼠。The selected fertilized eggs are transferred into the prepared M2 strips and arranged in a row (about 30-50 pieces). Place the syringe on the stage of the inverted microscope so that the strip of M2 droplets is oriented perpendicular to the operator, ie on the y-axis. The injection tube was inserted into the cytoplasm, and the Cas9sgRNA system (sgRNA and Cas9 mRNA) was injected. The Cas9 expression plasmid was cas9D10A (plasmid #42335), Addgene; and the cytoplasm was loose and the needle was quickly removed. After the end of the injection, the embryos were transferred to a Petri dish containing M16 medium and placed in a 37 ° C, 5% carbon dioxide incubator for 0.5-1.0 hours. The fertilized eggs were transplanted into the E0.5 day pseudopregnant recipient. F0 generation mice were born about 19-21 days after transplantation.
步骤五:F0代小鼠出生与鉴定Step 5: Birth and identification of F0 generation mice
出生小崽数量为39只,存活数量38只,F0代小鼠出生1周后进行剪尾鉴定,得到7只阳性F0代小鼠,毛色为黑色,性别为5雌2雄,图6为F1代两个雄性纯合Glrx1 -/-小鼠照片。 The number of birth defects was 39, and the number of surviving was 38. The F0 generation mice were identified by tail-cutting after 1 week of birth, and 7 positive F0 mice were obtained. The coat color was black, the sex was 5 females and 2 males, and Figure 6 was F1. A photo of two male homozygous Glrx1 -/- mice.
PCR反应体系:PCR reaction system:
PCR检测策略如图3所示。The PCR detection strategy is shown in Figure 3.
步骤六:F0小鼠性成熟配繁,F1代小鼠鉴定Step 6: Sexual maturity and F0 mice, F1 generation mouse identification
F0代小鼠在8周龄左右性成熟和C57BL/6J小鼠回交进行配繁,出生F1代小鼠在1周龄进行剪尾鉴定,得到6只阳性的F1代杂合子,列表如下:F0 mice were sexually matured at 8 weeks of age and C57BL/6J mice were backcrossed. The F1 mice were tail-tailed at 1 week of age, and 6 positive F1 heterozygotes were obtained. The list is as follows:
分别从mRNA水平和酶解测序来鉴定F1代,mRNA水平所采用qPCR手段来实现,条件同上。从测序结果可看出61#,62#,64#,73#,74#,75#与野生型对比序列长度至少少了-7588bp,也就是说明E1-E2被删掉。The F1 generation was identified from the mRNA level and enzymatic sequencing, and the mRNA level was achieved by qPCR. The conditions were the same as above. From the sequencing results, it can be seen that the length of the 61#, 62#, 64#, 73#, 74#, 75# and wild type comparison sequences is at least -7588 bp, which means that E1-E2 is deleted.
61#,62#,64#:61#,62#,64#:
73#,74#,75#:73#,74#,75#:
实施例2Example 2
本实施例与实施例1的不同点在于步骤三中所用单链DNA模板和引物序列为2074-Glrx-gtF1。其它步骤与实施例1相同;结果均与实施例1相同。This example differs from Example 1 in that the single-stranded DNA template and primer sequence used in step three are 2074-Glrx-gtF1. The other steps were the same as in Example 1; the results were the same as in Example 1.
实施例3Example 3
本实施例与实施例1的不同点在于步骤四中合笼雄鼠的品种优选为C57BL/6J雄鼠。其它步骤与实施例1相同。This example differs from Example 1 in that the variety of the caged male in step 4 is preferably a C57BL/6J male. The other steps are the same as in the first embodiment.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1918320.1A GB2578026B (en) | 2017-05-27 | 2018-05-03 | Method for constructing GLRX1 gene knock-out animal model based on CRISPR/CAS9 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710390894.3 | 2017-05-27 | ||
| CN201710390894.3A CN107287245B (en) | 2017-05-27 | 2017-05-27 | Construction method of Glrx1 gene knockout animal model based on CRISPR/Cas9 technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018219093A1 true WO2018219093A1 (en) | 2018-12-06 |
Family
ID=60095140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2018/085432 Ceased WO2018219093A1 (en) | 2017-05-27 | 2018-05-03 | Method for constructing glrx1 gene knock-out animal model based on crispr/cas9 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN107287245B (en) |
| GB (1) | GB2578026B (en) |
| WO (1) | WO2018219093A1 (en) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110157744A (en) * | 2019-06-13 | 2019-08-23 | 福建农林大学 | A honeybee CRISPR-Cas9 gene editing method |
| CN111518837A (en) * | 2020-04-02 | 2020-08-11 | 广州欣意生物技术有限公司 | Mouse with ADRB3 gene knocked out and application thereof |
| CN112662669A (en) * | 2020-12-23 | 2021-04-16 | 成都药康生物科技有限公司 | Il21 gene knockout mouse model and construction method and application thereof |
| CN112852803A (en) * | 2021-02-05 | 2021-05-28 | 上海市第六人民医院 | Construction method and application of systemic EEPD1 knockout animal model |
| CN113403311A (en) * | 2021-06-18 | 2021-09-17 | 南方科技大学 | sgRNA targeting casc5 gene and application thereof |
| CN113755498A (en) * | 2021-09-27 | 2021-12-07 | 赛业(苏州)生物科技有限公司 | gRNA of targeted mouse Ube3a gene and method for constructing AS disease mouse model |
| CN113862266A (en) * | 2021-09-18 | 2021-12-31 | 赛业(苏州)生物科技有限公司 | gRNA of targeted mouse BBS5 gene and method for constructing Bardet-Biedl mouse model |
| CN113957096A (en) * | 2021-10-26 | 2022-01-21 | 上海交通大学医学院附属第九人民医院 | Construction method of Nf1 gene knockout animal model |
| CN114317603A (en) * | 2022-01-12 | 2022-04-12 | 北京航空航天大学 | Construction method and application of Foxi3 gene site-directed mutagenesis mouse model |
| CN114958923A (en) * | 2022-06-28 | 2022-08-30 | 赛业(苏州)生物科技有限公司 | Construction method and application of Nr1d1 gene knockout mouse animal model |
| CN115044619A (en) * | 2022-05-25 | 2022-09-13 | 郑州大学第一附属医院 | A method for constructing a systemic inducible Ppp3ca knockout mouse model |
| CN115851829A (en) * | 2022-07-12 | 2023-03-28 | 温州医科大学附属眼视光医院 | Construction method of adenosine A2A receptor labeled mouse |
| CN115992178A (en) * | 2022-08-08 | 2023-04-21 | 首都医科大学附属北京天坛医院 | Preparation method and application of decorin transgenic mice |
| CN116064662A (en) * | 2022-09-07 | 2023-05-05 | 成都医学院第一附属医院 | A kind of Kank2-p.R621C gene mutation mouse model and its construction method and application |
| CN116445553A (en) * | 2023-04-13 | 2023-07-18 | 长沙市中心医院 | A kind of RBM15B gene knockout mouse model, construction method and application |
| CN116656747A (en) * | 2023-01-10 | 2023-08-29 | 广东医科大学附属医院 | Method for dynamically observing lysosome injury in vivo |
| CN116970646A (en) * | 2023-08-03 | 2023-10-31 | 首都医科大学附属北京天坛医院 | Construction method and application of gene knockout non-human animal model of meowing syndrome |
| CN117402879A (en) * | 2023-11-22 | 2024-01-16 | 中山大学附属口腔医院 | A method for constructing conditional knockout mice of SUV39H1 gene |
| US11926817B2 (en) | 2019-08-09 | 2024-03-12 | Nutcracker Therapeutics, Inc. | Microfluidic apparatus and methods of use thereof |
| CN117947095A (en) * | 2023-12-29 | 2024-04-30 | 上海实验动物研究中心 | A mouse model capable of inducing helper T cell 17 knockout and its construction method |
| CN118460610A (en) * | 2024-04-15 | 2024-08-09 | 华中科技大学同济医学院附属同济医院 | MBD2 conditional gene knockout mouse model, construction method and application thereof |
| CN118956953A (en) * | 2024-06-26 | 2024-11-15 | 中南大学湘雅医院 | Construction and application of an animal model of sudden death in epilepsy caused by Kcna1 gene knockout |
| WO2025137828A1 (en) * | 2023-12-25 | 2025-07-03 | 中国科学院深圳先进技术研究院 | Gene point mutation mouse model construction method |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| KR20250103795A (en) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Adenosine nucleobase editors and uses thereof |
| CN109804066A (en) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | Programmable CAS9- recombination enzyme fusion proteins and application thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| KR20190127797A (en) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Cytosine to Guanine Base Editing Agent |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| CN107287245B (en) * | 2017-05-27 | 2020-03-17 | 南京农业大学 | Construction method of Glrx1 gene knockout animal model based on CRISPR/Cas9 technology |
| CN111801345A (en) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | Methods and compositions for evolutionary base editors using phage-assisted sequential evolution (PACE) |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND PROCEDURES FOR PREDICTING REPAIR RESULTS IN GENE ENGINEERING |
| CN108410906A (en) * | 2018-03-05 | 2018-08-17 | 淮海工学院 | A kind of CRISPR/Cpf1 gene editing methods being applicable in Yu Haiyang shell-fish mitochondrial genomes |
| CN108642090A (en) * | 2018-05-18 | 2018-10-12 | 中国人民解放军总医院 | Method and the application that Nogo-B knocks out pattern mouse are obtained based on CRISPR/Cas9 technologies |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| CN109022485B (en) * | 2018-08-16 | 2021-02-02 | 华东师范大学 | Construction method, kit and application of optic atrophy animal model |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| CN109777837A (en) * | 2018-12-26 | 2019-05-21 | 首都医科大学 | A method for constructing a lethal gene systemic knockout mouse model using the CRISPR/Cas9 system |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CN109694885B (en) * | 2019-02-18 | 2021-03-02 | 中国人民解放军总医院 | Method for preparing PI3Kγ systemic knockout mice based on CRISPR/Cas9 technology and its application and kit |
| DE112020001306T5 (en) | 2019-03-19 | 2022-01-27 | Massachusetts Institute Of Technology | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES |
| CN110157704B (en) * | 2019-04-04 | 2021-08-06 | 中山大学 | A kind of mouse against mouse hepatitis virus and preparation method thereof |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN110218743B (en) * | 2019-04-25 | 2021-05-04 | 天津市环湖医院(天津市神经外科研究所、天津市脑系科中心医院) | A method for constructing a taurine transporter gene knockout rat model based on CRISPR/Cas9 technology |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN111109199B (en) * | 2019-11-22 | 2022-02-18 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Slc12a9 gene knockout mouse model and establishment method and application thereof |
| CN111321172A (en) * | 2019-12-27 | 2020-06-23 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | A method for establishing a CDK13 knockout animal model using CRISPR-Cas9 technology |
| JP2023525304A (en) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート,インコーポレーテッド | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN112899279B (en) * | 2021-03-08 | 2023-02-14 | 浙江大学 | Method for constructing Fzd6 gene knockout mouse model and application |
| CN112980880B (en) * | 2021-03-08 | 2023-05-02 | 浙江大学 | Method for constructing Fzd6-Q152E fixed-point mutation mouse model based on CRISPR/Cas9 and application |
| CN115058456B (en) * | 2022-06-23 | 2023-09-19 | 五邑大学 | Construction methods and applications of HPRT gene knockout animal models |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106282231A (en) * | 2016-09-06 | 2017-01-04 | 陕西慧康生物科技有限责任公司 | The construction method of mucopolysaccharidosis II type animal model and application |
| CN107287245A (en) * | 2017-05-27 | 2017-10-24 | 南京农业大学 | A kind of construction method of the Glrx1 Gene Knock-Out Animal Model models based on CRISPR/Cas9 technologies |
-
2017
- 2017-05-27 CN CN201710390894.3A patent/CN107287245B/en active Active
-
2018
- 2018-05-03 GB GB1918320.1A patent/GB2578026B/en active Active
- 2018-05-03 WO PCT/CN2018/085432 patent/WO2018219093A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106282231A (en) * | 2016-09-06 | 2017-01-04 | 陕西慧康生物科技有限责任公司 | The construction method of mucopolysaccharidosis II type animal model and application |
| CN107287245A (en) * | 2017-05-27 | 2017-10-24 | 南京农业大学 | A kind of construction method of the Glrx1 Gene Knock-Out Animal Model models based on CRISPR/Cas9 technologies |
Non-Patent Citations (1)
| Title |
|---|
| BACHSCHMID, M.M. ET AL.: "Attenuated Cardiovascular Hypertrophy and Oxidant Generation in Response to Angiotensin II Infusion in Glutaredoxin-1 Knockout Mice", FREE RADIC BIOL MED, vol. 49, no. 7, 15 October 2010 (2010-10-15), pages 1221 - 1229, XP055551337, ISSN: 0891-5849 * |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110157744A (en) * | 2019-06-13 | 2019-08-23 | 福建农林大学 | A honeybee CRISPR-Cas9 gene editing method |
| US12492394B2 (en) | 2019-08-09 | 2025-12-09 | Nutcracker Therapeutics, Inc. | Microfluidic apparatus and methods of use thereof |
| US11926817B2 (en) | 2019-08-09 | 2024-03-12 | Nutcracker Therapeutics, Inc. | Microfluidic apparatus and methods of use thereof |
| US12448618B2 (en) | 2019-08-09 | 2025-10-21 | Nutcracker Therapeutics, Inc. | Microfluidic apparatus and methods of use thereof |
| CN111518837A (en) * | 2020-04-02 | 2020-08-11 | 广州欣意生物技术有限公司 | Mouse with ADRB3 gene knocked out and application thereof |
| CN112662669A (en) * | 2020-12-23 | 2021-04-16 | 成都药康生物科技有限公司 | Il21 gene knockout mouse model and construction method and application thereof |
| CN112852803A (en) * | 2021-02-05 | 2021-05-28 | 上海市第六人民医院 | Construction method and application of systemic EEPD1 knockout animal model |
| CN112852803B (en) * | 2021-02-05 | 2023-10-31 | 上海市第六人民医院 | A method for constructing an animal model with systemic EEPD1 knockout and its application |
| CN113403311A (en) * | 2021-06-18 | 2021-09-17 | 南方科技大学 | sgRNA targeting casc5 gene and application thereof |
| CN113862266A (en) * | 2021-09-18 | 2021-12-31 | 赛业(苏州)生物科技有限公司 | gRNA of targeted mouse BBS5 gene and method for constructing Bardet-Biedl mouse model |
| CN113755498A (en) * | 2021-09-27 | 2021-12-07 | 赛业(苏州)生物科技有限公司 | gRNA of targeted mouse Ube3a gene and method for constructing AS disease mouse model |
| CN113957096A (en) * | 2021-10-26 | 2022-01-21 | 上海交通大学医学院附属第九人民医院 | Construction method of Nf1 gene knockout animal model |
| CN114317603B (en) * | 2022-01-12 | 2023-10-13 | 北京航空航天大学 | Construction method and application of Foxi3 gene site-directed mutagenesis mouse model |
| CN114317603A (en) * | 2022-01-12 | 2022-04-12 | 北京航空航天大学 | Construction method and application of Foxi3 gene site-directed mutagenesis mouse model |
| CN115044619A (en) * | 2022-05-25 | 2022-09-13 | 郑州大学第一附属医院 | A method for constructing a systemic inducible Ppp3ca knockout mouse model |
| CN115044619B (en) * | 2022-05-25 | 2023-09-15 | 郑州大学第一附属医院 | Construction method of whole-body inducible Ppp3ca gene knockout mouse model |
| CN114958923A (en) * | 2022-06-28 | 2022-08-30 | 赛业(苏州)生物科技有限公司 | Construction method and application of Nr1d1 gene knockout mouse animal model |
| CN115851829A (en) * | 2022-07-12 | 2023-03-28 | 温州医科大学附属眼视光医院 | Construction method of adenosine A2A receptor labeled mouse |
| CN115992178A (en) * | 2022-08-08 | 2023-04-21 | 首都医科大学附属北京天坛医院 | Preparation method and application of decorin transgenic mice |
| CN116064662A (en) * | 2022-09-07 | 2023-05-05 | 成都医学院第一附属医院 | A kind of Kank2-p.R621C gene mutation mouse model and its construction method and application |
| CN116656747B (en) * | 2023-01-10 | 2024-01-26 | 广东医科大学附属医院 | A method for dynamic observation of lysosomal damage in vivo |
| CN116656747A (en) * | 2023-01-10 | 2023-08-29 | 广东医科大学附属医院 | Method for dynamically observing lysosome injury in vivo |
| CN116445553A (en) * | 2023-04-13 | 2023-07-18 | 长沙市中心医院 | A kind of RBM15B gene knockout mouse model, construction method and application |
| CN116970646A (en) * | 2023-08-03 | 2023-10-31 | 首都医科大学附属北京天坛医院 | Construction method and application of gene knockout non-human animal model of meowing syndrome |
| CN117402879A (en) * | 2023-11-22 | 2024-01-16 | 中山大学附属口腔医院 | A method for constructing conditional knockout mice of SUV39H1 gene |
| WO2025137828A1 (en) * | 2023-12-25 | 2025-07-03 | 中国科学院深圳先进技术研究院 | Gene point mutation mouse model construction method |
| CN117947095A (en) * | 2023-12-29 | 2024-04-30 | 上海实验动物研究中心 | A mouse model capable of inducing helper T cell 17 knockout and its construction method |
| CN118460610A (en) * | 2024-04-15 | 2024-08-09 | 华中科技大学同济医学院附属同济医院 | MBD2 conditional gene knockout mouse model, construction method and application thereof |
| CN118956953A (en) * | 2024-06-26 | 2024-11-15 | 中南大学湘雅医院 | Construction and application of an animal model of sudden death in epilepsy caused by Kcna1 gene knockout |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2578026A (en) | 2020-04-15 |
| GB201918320D0 (en) | 2020-01-29 |
| CN107287245B (en) | 2020-03-17 |
| CN107287245A (en) | 2017-10-24 |
| GB2578026B (en) | 2022-11-23 |
| GB2578026A8 (en) | 2020-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107287245B (en) | Construction method of Glrx1 gene knockout animal model based on CRISPR/Cas9 technology | |
| CN107475300B (en) | Construction method and application of Ifit3-eKO1 knockout mouse animal model | |
| CN108660161B (en) | Method for preparing chimeric gene-free knockout animal based on CRISPR/Cas9 technology | |
| CN106047930B (en) | Preparation method of Flox rat with conditional knockout of PS1 gene | |
| CN110551759B (en) | Composition and method for improving recombination efficiency of transgenic cells | |
| CN105505879B (en) | Method and culture medium for culturing transgenic animal embryonic cells or transgenic animals | |
| CN110643636B (en) | A kind of method and application of knocking out MSTNa&b gene of bream | |
| CN108753834A (en) | The preparation method of ddx27 gene delection zebra fish mutant | |
| WO2018045727A1 (en) | Method for constructing an animal model for mucopolysaccharidosis type ii, and applications thereof | |
| JPWO2018030208A1 (en) | Method for producing gene knockin cell | |
| CN115807037B (en) | Breeding method of tetraploid fish with controllable inheritance and preparation method of triploid fish | |
| CN114908098A (en) | Preparation method and application of zebra fish hoxb1a gene deletion mutant | |
| CN113234756A (en) | Construction method of LAMA3 gene knockout animal model based on CRISPR/Cas9 technology | |
| CN113088521A (en) | Construction method of Ahnak2 gene knockout animal model based on CRISPR/Cas9 technology | |
| CN108893495A (en) | A kind of construction method of Pdzd7 gene mutant animals model | |
| CN111718933A (en) | Preparation method and application of an rrbp1 gene knockout tropical clawed frog model | |
| CN114934073A (en) | Construction methods and applications of hoxa1a knockout zebrafish mutants | |
| CN111549070B (en) | Method for editing X chromosome multicopy gene to realize animal sex control | |
| CN118185948B (en) | Construction and application of Cfap46 gene knockout mouse animal model | |
| CN111849977B (en) | Method for preparing transgenic animals by sperm vector, sgRNA for preparing short and small transgenic chickens and preparation method | |
| CN108715862A (en) | The preparation method of ddx19 gene delection zebra fish mutant | |
| CN114480497B (en) | Construction and application method of ep400 gene knockout zebra fish heart failure model | |
| CN117867016A (en) | A method for obtaining a fast-growing red crucian carp homozygous strain by knocking out the mstnb gene | |
| CN115261360A (en) | A method for constructing a gata6 knockout zebrafish model | |
| CN111518839B (en) | An allele-specific site editing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18809204 Country of ref document: EP Kind code of ref document: A1 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 201918320 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20180503 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18809204 Country of ref document: EP Kind code of ref document: A1 |